HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia.

AuthorsLawrence H Young, Katharine J Henderson, Robert I White, Guadalupe Garcia-Tsao
JournalHepatology (Baltimore, Md.) (Hepatology) Vol. 58 Issue 1 Pg. 442-5 (Jul 2013) ISSN: 1527-3350 [Electronic] United States
PMID23686865 (Publication Type: Journal Article, Comment)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Arteriovenous Malformations (etiology)
  • Cardiac Output (drug effects)
  • Female
  • Humans
  • Liver (blood supply)
  • Male
  • Telangiectasia, Hereditary Hemorrhagic (drug therapy, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: